NCT06930742Not yet recruiting
Mindfulness-Enhanced Dual-Task Training in PD-MCI
Mindfulness-Enhanced Cognitive-Motor Dual-Task Training Using Balance and Isokinetic Systems for Parkinson's Disease With Mild Cognitive Impairment: A Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 16 Apr 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this clinical trial is to learn if Mindfulness-Enhanced Dual-Task Training work to treat PD-MCI in adults. The main questions it aims to answer are: Does Mindfulness-Enhanced Dual-Task Training improve the cognitive or motor function of participants? Can the combination of Dual-Task Training and Mindfulness achieve better effects? Researchers will compare 3 groups (Dual-Task Training + Mindfulness, Dual-Task Training, and conventional motor task training) to see if Dual-Task Training and Mindfulness works to treat PD-MCI. Participants will: Receive treatment for 4 weeks Receive scale and instrument testing before and after treatment
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- First submitted
- 9 Apr 2025
- Start date
- 1 May 2025
- Primary completion date
- 30 Jul 2025
- Lead sponsor
- Nanjing Mingzhou Rehabilitation Hospital
- Diseases
- Parkinson disease
- NCT number
- NCT06930742
What you commit to
- Study type: Interventional
- Planned participants: 90
- From 1 May 2025 to the primary completion date, 30 Jul 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Other Neurological Disorders: Presence of other neurological conditions that could affect cognitive function, such as Alzheimer's disease, stroke, or brain tumors.
- Psychiatric Conditions: Severe psychiatric disorders, including major depressive disorder or schizophrenia.
- Substance Abuse: Recent history of drug or alcohol abuse.
- Serious Medical Conditions: Uncontrolled hypertension, diabetes, heart disease, or other conditions that could interfere with study participation or outcomes.
- Severe Cognitive Impairment: Diagnosis of Parkinson's Disease Dementia (PDD).
- Other Factors Affecting Cognition: Recent head trauma, uncontrolled thyroid dysfunction, vitamin B12 deficiency, or other conditions known to affect cognitive function.
- Deep Brain Stimulation (DBS): History of DBS treatment. Participation in Other Clinical Trials: Participation in another clinical trial that could interfere with this study within the last 3 months.
Who the study is looking for
- Age: Between 55 and 75 years.
- Disease Diagnosis: Clinically diagnosed with Idiopathic Parkinson's Disease (PD) according to the UK Parkinson's Disease Society Brain Bank Criteria.
- Disease Stage: Hoehn \& Yahr (H\&Y) stages 1 to 2.5.
- Cognitive Function: Montreal Cognitive Assessment (MoCA) score between 23 and 26, indicating mild cognitive impairment (MCI).
- Medication Stability: Stable doses of antiparkinsonian medications for at least 4 weeks prior to screening.
- Subjective Cognitive Complaints: Self-reported or informant-reported cognitive decline persisting for at least 6 months.
- Ambulatory Ability: Able to walk independently, with or without assistive devices.
- Sensory Abilities: Adequate vision and hearing to comply with study procedures.
- Informed Consent: Willingness to provide written informed consent and comply with study requirements.
Age in the registry: 55 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Nanjing Mingzhou Rehabilitation Hospital Coordinator of this site? Confirm its status | Nanjing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.